{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:10:01Z","timestamp":1784758201563,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.clinthera.2015.05.001","type":"journal-article","created":{"date-parts":[[2015,6,20]],"date-time":"2015-06-20T00:47:55Z","timestamp":1434761275000},"page":"1493-1502","source":"Crossref","is-referenced-by-count":20,"title":["Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus"],"prefix":"10.1016","volume":"37","clinical-trial-number":[{"clinical-trial-number":"nct01316341","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Xia","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uli C.","family":"Broedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Salsali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Pinnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreeraj","family":"Macha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.05.001_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(11)60679-X","article-title":"National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants","volume":"378","author":"Danaei","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.05.001_bib2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.diabres.2009.10.007","article-title":"Global estimates of the prevalence of diabetes for 2010 and 2030","volume":"87","author":"Shaw","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clinthera.2015.05.001_bib3","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.2013.168118","article-title":"Prevalence and control of diabetes in Chinese adults","volume":"310","author":"Xu","year":"2013","journal-title":"JAMA"},{"issue":"suppl 2","key":"10.1016\/j.clinthera.2015.05.001_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.17.S2.1","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan","volume":"17","author":"Handelsman","year":"2011","journal-title":"Endocr Pract"},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2015.05.001_bib5","first-page":"8","article-title":"Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study","volume":"10","author":"Alvarez","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2015.05.001_bib6","first-page":"4175","article-title":"A nationwide survey of diabetes education, self-management and glycemic control in patients with type 2 diabetes in China","volume":"125","author":"Guo","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.clinthera.2015.05.001_bib7","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2015.05.001_bib8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","article-title":"Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications","volume":"27","author":"Gerich","year":"2010","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2015.05.001_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1463-1326.2011.01511.x","article-title":"The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia","volume":"14","author":"Defronzo","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2015.05.001_bib10","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1038\/ki.2010.512","article-title":"Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans","author":"List","year":"2011","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.clinthera.2015.05.001_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2015.05.001_bib12","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2015.05.001_bib13","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/dom.12081","article-title":"A phase IIb, randomised, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes","volume":"15","author":"Ferrannini","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2015.05.001_bib14","first-page":"A282","article-title":"Empagliflozin as add-on to metformin for 24 weeks improves glycemic control in patients with type 2 diabetes (T2DM)","volume":"62","author":"H\u00e4ring","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2015.05.001_bib15","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/dom.12185","article-title":"Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia","volume":"15","author":"Rosenstock","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2015.05.001_bib16","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial","volume":"36","author":"H\u00e4ring","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2015.05.001_bib17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dom.12188","article-title":"Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial","volume":"16","author":"Kovacs","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2015.05.001_bib18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2133\/dmpk.DMPK-12-RG-082","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, in healthy Japanese subjects","volume":"28","author":"Sarashina","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.clinthera.2015.05.001_bib19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/cpdd.16","article-title":"Empagliflozin (BI 10773), a potent and selective SGLT-2 inhibitor, induces dose-dependent glucosuria in healthy subjects","volume":"2","author":"Seman","year":"2013","journal-title":"Clinical Pharm Drug Dev"},{"key":"10.1016\/j.clinthera.2015.05.001_bib20","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/dom.12073","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks\u05f3 treatment with empagliflozin once daily in patients with type 2 diabetes","volume":"15","author":"Heise","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2015.05.001_bib21","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/jdi.12110","article-title":"Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks\u05f3 treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus","volume":"4","author":"Kanada","year":"2013","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.clinthera.2015.05.001_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-013-0104-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2","volume":"53","author":"Kasichayanula","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2015.05.001_bib23","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.clinthera.2013.06.017","article-title":"Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects","volume":"35","author":"Yang","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2015.05.001_bib24","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jcph.88","article-title":"Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus","volume":"53","author":"Devineni","year":"2013","journal-title":"J Clin Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815002854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815002854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T16:28:28Z","timestamp":1537547308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815002854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0149291815002854"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.05.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}